Evidence map›Paper›PMID 32901838›Full record

ArticleMolecular medicine reports2020

Long non‑coding RNA TP73‑AS1 accelerates the progression and cisplatin resistance of non‑small cell lung cancer by upregulating the expression of TRIM29 via competitively targeting microRNA‑34a‑5p.

Shunxiang Luo, Ming Shen, Hui Chen, Weiwei Li, Cong Chen

Open access · hybridAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Molecular medicine reports, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers.

0numbers the graph read from it
0cells of the map it votes in
17citing papers in PubMed
1.5field-weighted citation impact, top 18% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

17 citing papers in PubMed, 27 citations in OpenAlex.

  1. Trial
  2. Article
  3. Article
  4. Review
  5. Review
  6. Review
  7. Review
  8. Review
  9. Review
  10. Article
  11. Review
  12. Article
  13. Review
  14. Article
  15. Review
  16. Article
  17. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 1 institution in 1 country.

Shunxiang LuoDepartment of Oncology, The First People's Hospital of Tianmen, Tianmen, Hubei 431700, P.R. China.
Ming ShenDepartment of Oncology, The First People's Hospital of Tianmen, Tianmen, Hubei 431700, P.R. China.
Hui ChenDepartment of Oncology, The First People's Hospital of Tianmen, Tianmen, Hubei 431700, P.R. China.
Weiwei LiDepartment of Oncology, The First People's Hospital of Tianmen, Tianmen, Hubei 431700, P.R. China.
Cong ChenDepartment of Oncology, The First People's Hospital of Tianmen, Tianmen, Hubei 431700, P.R. China.
The First People's Hospital of Tianmen · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Non‑small cell lung cancer (NSCLC) is a leading subtype of lung cancer, with high mortality rates. Recently, long non‑coding RNAs (lncRNAs) have been associated with NSCLC. The present study aimed to examine the role of the TP73 antisense RNA 1 (TP73‑AS1) lncRNA in NSCLC. TP73‑AS1 and microRNA(miR)‑34a‑5p expression levels were measured using reverse transcription‑quantitative PCR (RT‑qPCR) and chromogenic in situ hybridization (CISH). Cell proliferation, apoptosis, migration and invasion was determined using Cell Counting Kit‑8 (CCK‑8), flow cytometry, Transwell and Matrigel assays, respectively. The median inhibitory concentration (IC50) value of cisplatin (cis‑diamminedichloroplatinum; DDP) was assessed using a CCK‑8 assay. The interaction between miR‑34a‑5p and TP73‑AS1 or tripartite motif‑containing 29 (TRIM29) was predicted using microRNA.org and Starbase, then verified using a dual‑luciferase reporter assay. The expression of TRIM29 was quantified at the mRNA and protein level using RT‑qPCR and western blot analysis, respectively. TP73‑AS1 was significantly upregulated, while miR‑34a‑5p was downregulated in NSCLC tissues and cells. Functionally, TP73‑AS1 knockdown inhibited proliferation, migration, invasion and DDP resistance, whilst inducing apoptosis in NSCLC cells. miR‑34a‑5p was identified as a target for TP73‑AS1, and its inhibition reversed the effects of TP73‑AS1 knockdown on NSCLC cells. In addition, TRIM29 was targeted by miR‑34a‑5p, and its overexpression reversed the effects of miR‑34a‑5p. Moreover, TP73‑AS1 acted as a molecular sponge for miR‑34a‑5p, increasing the expression of TRIM29. In conclusion, TP73‑AS1 contributed to proliferation, migration and DDP resistance but inhibited apoptosis of NSCLC cells by upregulating TRIM29 and sponging miR‑34a‑5p.

Indexed as

Drug Resistance, NeoplasmCarcinoma, Non-Small-Cell LungCell Line, TumorCell MovementCell ProliferationCell SurvivalCisplatinDisease ProgressionDNA-Binding ProteinsFemaleGene Expression Regulation, NeoplasticHumansLung NeoplasmsMaleMicroRNAsNeoplasm StagingCisplatinDNA-Binding Proteinslong non-coding RNA KIAA0495, humanMicroRNAsMIRN34 microRNA, humanRNA, Long NoncodingTranscription FactorsTRIM29 protein, human

Identifiers

PMID32901838
PMCPMC7533438
OpenAlexW3082928302

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.